Ken Griffin Astria Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$8.83 - $13.51 $1.25 Million - $1.91 Million	-141,300 Reduced 92.47%	11,500 $104,000
Q1 2024 May 15, 2024	BUY	$6.99 - $16.69 $922,680 - $2.2 Million	132,000 Added 634.62%	152,800 $2.15 Million
Q4 2023 Feb 14, 2024	BUY	$4.42 - $8.06 $55,692 - $101,556	12,600 Added 153.66%	20,800 $159,000
Q3 2023 Nov 14, 2023	BUY	$6.89 - $9.86 $11,713 - $16,762	1,700 Added 26.15%	8,200 $61,000
Q2 2023 Aug 14, 2023	BUY	$8.33 - $13.72 $15,827 - $26,068	1,900 Added 41.3%	6,500 $54,000
Q1 2023 May 15, 2023	SELL	$11.2 - $15.79 $38,080 - $53,686	-3,400 Reduced 42.5%	4,600 $61,000
Q4 2022 Feb 14, 2023	BUY	$7.44 - $14.89 $59,520 - $119,120	8,000 New	8,000 $119,000

102

49.4M

27.6K

29.7K

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $170M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.